-	against feline viral rhinotracheitis to reduce clinical signs,
-	against calicivirus infection to reduce clinical signs,
-	against Chlamydophila felis infection to reduce clinical signs,
-	against feline panleucopenia to prevent mortality and clinical signs,
-	against leukaemia to prevent persistent viraemia and clinical signs of the related disease.

Onset of immunity: Rhinotracheitis, calicivirus, Chlamydophila felis and panleucopenia components: 1 week after primary vaccination course.
Feline leukaemia component: 2 weeks after primary vaccination course.

Duration of immunity:

-	Rhinotracheitis, calicivirosis and panleucopenia components: 1 year after primary vaccination course and 3 years after the last re-vaccination.
-	Chlamydophila felis and feline leukaemia components: 1 year after the last re-vaccination.

Dose to be administered and administration route

Subcutaneous route.

Reconstitute gently the vaccine in order to obtain a uniform suspension with limited foam formation.
Visual appearance after reconstitution: slightly yellow suspension with presence of cell debris in suspension.

After reconstitution of the lyophilisate with 0.5 ml or 1 ml of the solvent (depending on the presentation chosen) inject one dose of vaccine according to the following vaccination scheme:

Primary vaccination course:

-	first injection: from 8 weeks of age.
-	second injection: 3 to 4 weeks later.

Where high levels of maternal antibodies against rhinotracheitis, calicivirosis, panleucopenia or Chlamydophila components are expected to be present (e.g. in kittens of 9 to 12 weeks of age born from queens, which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.

Revaccination:

-	the first revaccination must be carried out for all components one year after the primary vaccination course,
-	subsequent revaccinations:
	-	Chlamydiosis and feline leukaemia components: every year.
	-	Rhinotracheitis, calicivirosis and panleucopenia components: at intervals of up to three years.

Adverse reactions

Cats

Common

(1 to 10 animals / 100 animals treated):

Transient apathy, anorexia, and hyperthermia¹ (observed during safety and field studies).

Injection site reactions (slight pain at palpation, itching or limited oedema)² (observed during safety and field studies)

Uncommon

(1 to 10 animals / 1,000 animals treated):

Hypersensitivity reaction³ (observed in field studies)

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Emesis⁴; transient hyperthermia and lethargy, sometimes associated with lameness⁵ (based on post-marketing experience)

¹lasting usually for 1 or 2 days
²disappearing within 1 or 2 weeks at most
³may require appropriate symptomatic treatment
⁴mostly within 24 to 48 hours
⁵ observed 1 to 3 weeks following booster vaccination in adult cats

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the last section of the package leaflet for respective contact details.